Bin Tian appointed professor, co-director of the Center for Systems & Computational Biology at Wistar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bin Tian was appointed professor at the The Wistar Institute Cancer Center.

A molecular biologist by training, Tian focuses on RNA biology and understanding how gene expression is regulated at the post-transcriptional level. His research involves interdisciplinary approaches, including molecular biology, genomics and computational biology, to study RNA biogenesis and metabolism. His lab was among the first to characterize the functional genomics of alternative polyadenylation and has uncovered its role in many diverse cellular processes.

“Bin’s research has led to groundbreaking advances understanding the role of alternative polyadenylation in development and cell differentiation as well as in the context of cancer and cellular stress,” Dario C. Altieri, Wistar president and CEO, director of the Cancer Center, and the Robert and Penny Fox Distinguished Professor, said in a statement. “Bin’s work strengthens our RNA biology research and brings expertise in complex computational and genomic methods that will synergize with the work of our scientists across our research programs.”

Tian joins Wistar from Rutgers New Jersey Medical School, where he was a professor. In 2003, he established his research group at Rutgers New Jersey Medical School where he became a tenured professor in 2014.

Table of Contents

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login